• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

B细胞活化与耐受的淋巴瘤模型。IV. 抗Ig对CH31和CH33 B淋巴瘤细胞的生长抑制作用

Lymphoma models for B cell activation and tolerance. IV. Growth inhibition by anti-Ig of CH31 and CH33 B lymphoma cells.

作者信息

Pennell C A, Scott D W

出版信息

Eur J Immunol. 1986 Dec;16(12):1577-81. doi: 10.1002/eji.1830161217.

DOI:10.1002/eji.1830161217
PMID:3493148
Abstract

CH31 and CH33 are B cell lymphomas whose growth in vitro is inhibited by anti-Ig reagents, including both polyclonal and monoclonal anti-mu antibodies, and an anti-idiotype antiserum. Antibodies against class I or class II major histocompatibility complex antigens do not affect the growth of these cells. Inhibition is dependent on surface Ig cross-linking and does not require ligand binding to Fc receptors. Interestingly, the inhibition of growth by anti-mu is reversed in CH31 (but not CH33) by E. coli lipopolysaccharide. These lymphomas should provide excellent models to study the mechanisms of growth inhibition mediated by surface Ig cross-linking and the pathways of its reversal.

摘要

CH31和CH33是B细胞淋巴瘤，其体外生长受到抗Ig试剂的抑制，这些试剂包括多克隆和单克隆抗μ抗体以及一种抗独特型抗血清。针对I类或II类主要组织相容性复合体抗原的抗体不影响这些细胞的生长。抑制作用依赖于表面Ig交联，且不需要配体与Fc受体结合。有趣的是，在CH31（而非CH33）中，大肠杆菌脂多糖可逆转抗μ对生长的抑制作用。这些淋巴瘤应为研究表面Ig交联介导的生长抑制机制及其逆转途径提供极佳的模型。

相似文献

1
Lymphoma models for B cell activation and tolerance. IV. Growth inhibition by anti-Ig of CH31 and CH33 B lymphoma cells.B细胞活化与耐受的淋巴瘤模型。IV. 抗Ig对CH31和CH33 B淋巴瘤细胞的生长抑制作用
Eur J Immunol. 1986 Dec;16(12):1577-81. doi: 10.1002/eji.1830161217.
2
Lymphoma models for B cell activation and tolerance. V. Anti-Ig mediated growth inhibition is reversed by phorbol myristate acetate but does not involve changes in cytosolic free calcium.用于B细胞激活和耐受的淋巴瘤模型。V.佛波醇肉豆蔻酸酯乙酸盐可逆转抗Ig介导的生长抑制，但不涉及胞质游离钙的变化。
J Mol Cell Immunol. 1987;3(2):109-20.
3
Lymphoma models for B cell activation and tolerance. VI. Reversal of anti-Ig-mediated negative signaling by T cell-derived lymphokines.用于B细胞激活和耐受的淋巴瘤模型。VI. T细胞衍生的淋巴因子对抗Ig介导的负信号的逆转。
J Immunol. 1987 Dec 15;139(12):3924-9.
4
The influence of avidity on signaling murine B lymphocytes with monoclonal anti-IgM antibodies. Effects of B cell proliferation versus growth inhibition (tolerance) of an immature B cell lymphoma.亲和力对用单克隆抗IgM抗体刺激小鼠B淋巴细胞信号传导的影响。未成熟B细胞淋巴瘤的B细胞增殖与生长抑制（耐受）的作用。
J Immunol. 1991 Jun 15;146(12):4120-9.
5
Lymphoma models for B cell activation and tolerance. I. Conditions for the anti-mu-dependent stimulation of growth in NBL, a nude B cell lymphoma.B细胞活化与耐受的淋巴瘤模型。I. 裸鼠B细胞淋巴瘤（NBL）中抗μ依赖性生长刺激的条件。
J Immunol. 1985 Mar;134(3):1449-54.
6
A polyclonal model for B cell tolerance. I. Fc-dependent and Fc-independent induction of nonresponsiveness by pretreatment of normal splenic B cells with anti-Ig.B细胞耐受性的多克隆模型。I. 用抗Ig预处理正常脾B细胞对无反应性的Fc依赖性和Fc非依赖性诱导
J Immunol. 1991 Apr 1;146(7):2185-91.
7
Anti-immunoglobulin antibodies induce apoptosis in immature B cell lymphomas.抗免疫球蛋白抗体可诱导未成熟B细胞淋巴瘤发生凋亡。
Eur J Immunol. 1990 Aug;20(8):1685-90. doi: 10.1002/eji.1830200810.
8
Cross-linking of B lymphocyte Fc gamma receptors and membrane immunoglobulin inhibits anti-immunoglobulin-induced blastogenesis.B淋巴细胞Fcγ受体与膜免疫球蛋白的交联抑制抗免疫球蛋白诱导的母细胞生成。
J Immunol. 1984 Feb;132(2):627-32.
9
Production of multiple lymphokines by the A20.1 B cell lymphoma after cross-linking of membrane Ig by immobilized anti-Ig.
J Immunol. 1989 Aug 1;143(3):881-9.
10
The synergistic effects of anti-IgM and monoclonal anti-Ia antibodies in induction of murine B lymphocyte activation.抗 IgM 抗体和单克隆抗 Ia 抗体在诱导小鼠 B 淋巴细胞活化中的协同作用。
J Mol Cell Immunol. 1988;4(1):45-57.

引用本文的文献

1
Strategies in the design of nanoparticles for therapeutic applications.用于治疗应用的纳米粒子设计策略。
Nat Rev Drug Discov. 2010 Aug;9(8):615-27. doi: 10.1038/nrd2591. Epub 2010 Jul 9.
2
CTCF functions as a critical regulator of cell-cycle arrest and death after ligation of the B cell receptor on immature B cells.CTCF作为未成熟B细胞上B细胞受体连接后细胞周期停滞和死亡的关键调节因子发挥作用。
Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):633-8. doi: 10.1073/pnas.0237127100. Epub 2003 Jan 10.
3
Ligation of CD40 with soluble CD40 ligand reverses anti-immunoglobulin-mediated negative signalling in murine B lymphoma cell lines but not in immature B cells from neonatal mice.
用可溶性CD40配体连接CD40可逆转抗免疫球蛋白介导的小鼠B淋巴瘤细胞系中的负信号传导，但对新生小鼠的未成熟B细胞无效。
Immunology. 1996 Apr;87(4):624-32. doi: 10.1046/j.1365-2567.1996.517595.x.
4
Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma.抗原结合受体的合成肽配体可诱导人B细胞淋巴瘤中的程序性细胞死亡。
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3623-7. doi: 10.1073/pnas.91.9.3623.
5
Antisense oligodeoxynucleotides to the blk tyrosine kinase prevent anti-mu-chain-mediated growth inhibition and apoptosis in a B-cell lymphoma.
Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7946-50. doi: 10.1073/pnas.90.17.7946.
6
Immunoglobulins D and M mediate signals that are qualitatively different in B cells with an immature phenotype.免疫球蛋白D和M介导的信号在具有未成熟表型的B细胞中在性质上有所不同。
Proc Natl Acad Sci U S A. 1988 Sep;85(18):6919-23. doi: 10.1073/pnas.85.18.6919.
7
Immunoglobulin receptor signaling depends on the carboxyl terminus but not the heavy-chain class.免疫球蛋白受体信号传导取决于羧基末端而非重链类别。
Proc Natl Acad Sci U S A. 1989 Mar;86(6):1977-81. doi: 10.1073/pnas.86.6.1977.
8
Antigen receptor-induced cell cycle arrest in WEHI-231 B lymphoma cells depends on the duration of signaling before the G1 phase restriction point.抗原受体诱导的WEHI-231 B淋巴瘤细胞周期停滞取决于G1期限制点之前的信号传导持续时间。
Mol Cell Biol. 1990 Jun;10(6):3003-12. doi: 10.1128/mcb.10.6.3003-3012.1990.
9
Intrinsic B-cell hyporesponsiveness accounts for self-tolerance in lysozyme/anti-lysozyme double-transgenic mice.内在B细胞低反应性导致溶菌酶/抗溶菌酶双转基因小鼠的自身耐受性。
Proc Natl Acad Sci U S A. 1990 Aug;87(15):5687-91. doi: 10.1073/pnas.87.15.5687.